Before revision: Heparin is administered intravenously as an anticoagulant to COVID-19 patients and via aerosol to treat other lung diseases. It has recently been found to have antiviral activity against SARS-CoV-2 as it hinders attachment of the virus to the host cell by binding to the virus spike glycoprotein .
After revision: Heparin has been found to have antiviral activity against SARS-CoV-2 as it hinders attachment of the virus to the host cell by binding to the virus spike glycoprotein .